An observational study of burden of upper GI-symptoms in CV risk patients
Study identifier:D961FC00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A prospective descriptive, multi-national, multi-centre observational study of burden of upper GI-symptoms in subjects with cardiovascular risk or disease receiving treatment with low-dose aspirin
Medical condition
cardiovascular disease
Phase
-
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
1836
Study type
Observational
Age
18 Years +
Date
Study Start Date: 01 Jan 2008
Primary Completion Date: -
Study Completion Date: 01 Sept 2008
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| 1 Patients who have been prescribed Low Dose Aspirin (LDA) usage in the past 12 months, or those about to begin LDA, will complete a one-time in-office survey using an electronic personal digital assistant (PDA) device (termed SitePro). | - |
| 2 420 subjects stratified into three groups varying on length of time using Low Dose Aspirin (LDA) | - |
| 3 Up to 20 subjects from the three EMA groups will be interviewed to further debrief their experience with Low Dose Aspirin (LDA) and upper GI symptoms. | - |
